Effect of antifoaming agent on benign colorectal tumors in colonoscopy: A meta-analysis

Table 3 Sensitivity analyses and subgroup analyses of the studies included in the meta-analysis

	Number of trials	Number of patients	OR/MD (95%CI)	P value	I2	Study associated with heterogeneity
Primary outcome
ADR	9	4069	1.01 (0.88-1.15)	0.94	41%	-
Proportion of ADR
< 25%	3	1299	1.55 (1.16-2.07)	0.003	0%	-
≥ 25%	6	2770	0.88 (0.76-1.03)	0.12	0%	-
Dose of simethicone
≥ 400 mg	5	1806	1.21 (0.97-1.50)	0.09	50%	-
< 400 mg and NR	4	2263	0.89 (0.75-1.06)	0.20	0%
Size of adenoma
< 10 mm	2	1155	2.36 (1.79-3.10)	< 0.00001	29%	-
≥ 10 mm	2	1155	1.39 (0.67-2.86)	0.38	0%	-
Location of adenoma
Right colon	3	1299	2.61 (1.43-4.76)	0.002	58%	Bai 2018 (I2 = 45%)
Left colon	3	1299	1.44 (1.02-2.02)	0.04	23%	-
Regions of the populations
Asia	3	1415	1.45 (1.12-1.87)	0.005	0%	-
Not-Asia	5	2386	0.88 (0.74-1.04)	0.14	0%	-
PDR	10	4544	1.13 (0.89-1.42)	0.31	64%	Valiante 2013 (I2 = 41%)
Dose of simethicone
≥ 400 mg	4	1546	1.06 (0.80-1.41)	0.67	40%
< 400 mg and NR	6	2998	1.23 (0.85-1.79)	0.28	74%	Valiante 2013 (I2 = 41%)
Size of adenoma
< 10 mm	3	2498	0.93 (0.79-1.09)	0.37	46%	-
≥ 10 mm	2	2128	0.98 (0.78-1.22)	0.84	0%	-
Proportion of PDR
< 40%	4	1487	1.29 (0.97-1.72)	0.08	31%	-
≥ 40%	6	3057	1.03 (0.75-1.41)	0.86	67%	Valiante 2013 (I2 = 0%)
Regions of the populations
Asia	2	1155	1.24 (0.95-1.62)	0.11	14%	-
Not-Asia	8	3389	1.10 (0.82-1.47)	0.53	66%	Valiante 2013 (I2 = 22%)
Secondary outcome
Adverse events
Bloating	11	3049	0.51 (0.36-0.73)	0.0002	67%	Repici 2012 (I² = 49%)
Nausea	14	3397	1.03 (0.87-1.22)	0.69	33%	-
Vomiting	9	2514	1.02 (0.75-1.40)	0.89	0%	-
Abdominal pain	15	3669	0.89 (0.72-1.10)	0.29	42%	-
Sleep disturbance	9	1990	0.81 (0.64-1.01)	0.06	25%	-

ADR: Detection rate of colorectal adenoma; MD: Mean difference; NR: Not reported; OR: Odds ratio; PDR: Detection rate of colorectal polyp.